EA201491500A1 - Способы лечения фиброза - Google Patents

Способы лечения фиброза

Info

Publication number
EA201491500A1
EA201491500A1 EA201491500A EA201491500A EA201491500A1 EA 201491500 A1 EA201491500 A1 EA 201491500A1 EA 201491500 A EA201491500 A EA 201491500A EA 201491500 A EA201491500 A EA 201491500A EA 201491500 A1 EA201491500 A1 EA 201491500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibroza
treatment methods
fibrosis
methods
administering
Prior art date
Application number
EA201491500A
Other languages
English (en)
Other versions
EA030762B1 (ru
Inventor
Серджо Барони
Сальваторе Беллинвия
Франческа Вити
Original Assignee
Ногра Фарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ногра Фарма Лимитед filed Critical Ногра Фарма Лимитед
Publication of EA201491500A1 publication Critical patent/EA201491500A1/ru
Publication of EA030762B1 publication Critical patent/EA030762B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Изобретение направлено на способы лечения фиброза, например фиброза печени и/или фиброза кишечника, включающие введение пациенту, которому это необходимо, эффективного количества соединения по настоящему изобретению.
EA201491500A 2012-02-09 2013-02-08 Способы лечения фиброза EA030762B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12425027 2012-02-09
US201261644544P 2012-05-09 2012-05-09
PCT/EP2013/052617 WO2013117744A2 (en) 2012-02-09 2013-02-08 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
EA201491500A1 true EA201491500A1 (ru) 2015-01-30
EA030762B1 EA030762B1 (ru) 2018-09-28

Family

ID=48948116

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491500A EA030762B1 (ru) 2012-02-09 2013-02-08 Способы лечения фиброза

Country Status (12)

Country Link
US (3) US9682923B2 (ru)
EP (2) EP3628317A1 (ru)
JP (2) JP6301844B2 (ru)
KR (1) KR102067848B1 (ru)
CN (3) CN116602950A (ru)
AU (1) AU2013217933B2 (ru)
BR (1) BR112014019399A2 (ru)
CA (1) CA2864059C (ru)
EA (1) EA030762B1 (ru)
IL (3) IL233968A (ru)
MX (1) MX364220B (ru)
WO (1) WO2013117744A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2396081T (pt) 2009-02-16 2017-07-11 Nogra Pharma Ltd Compostos alquilamido e suas utilizações
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
BR112014026160A2 (pt) 2012-04-18 2017-07-18 Nogra Pharma Ltd métodos para tratar intolerância à lactose
WO2017046343A1 (en) * 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) * 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
US11162097B2 (en) * 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
EA202192207A1 (ru) 2019-02-08 2021-10-27 Ногра Фарма Лимитед Способ получения 3-(4'-аминофенил)-2-метоксипропионовой кислоты и ее аналогов и промежуточных соединений
WO2022069701A1 (en) * 2020-10-01 2022-04-07 Nogra Pharma Limited Methods of treating pulmonary fibrosis

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3786452T2 (de) 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
US4933330A (en) 1987-04-01 1990-06-12 Dak-Laboratoriet Benzoic acid derivatives and use thereof
EP0352826B1 (en) 1988-05-05 1994-10-26 Tillotts Pharma Ag Use of 5-aminosalicylic acid in the treatment of dermatological disorders
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
JP3425441B2 (ja) 1990-10-22 2003-07-14 ガストロ サービシイズ ピーティーワイ リミテッド 非炎症性及び非感染性腸障害の処置
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
ATE211466T1 (de) 1992-03-17 2002-01-15 Fujisawa Pharmaceutical Co Depsipeptide, herstellung und anwendung
ATE214608T1 (de) 1992-06-30 2002-04-15 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
EP0759750A4 (en) 1994-05-11 1998-05-27 Howard K Shapiro PREPARATIONS FOR TREATING CHRONIC FLAMMABLE DISEASES
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
JPH10511097A (ja) 1995-03-28 1998-10-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 低薬用量リドグレル調合物および炎症性腸疾患の処置のためのそれらの使用
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
WO1999015520A1 (fr) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
DE69832520T2 (de) 1997-12-12 2006-08-10 Purdue Research Foundation, West Lafayette Verwendung von konjugierten linoleinsäure zur behandlung von type ii diabetes
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
JP3854154B2 (ja) 2000-04-19 2006-12-06 ニューロテック カンパニー リミテッド 中枢神経系の急性及び慢性的損傷に起因した神経変性を防止するための化合物、組成物及び方法
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
AU2001258838A1 (en) 2000-05-29 2001-12-11 Kyorin Pharmaceutical Co. Ltd. Substituted phenylpropionic acid derivatives
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
JPWO2002046161A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
EP1389044A4 (en) 2001-04-18 2006-07-05 Merck & Co Inc PPAR-ALPHA-GAMMA AGONISTS OR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
CN1589258A (zh) 2001-10-16 2005-03-02 雷迪实验室有限公司 新的β－苯基－α－氧取代的丙酸衍生物,它的制备方法和它们制备药学上重要的化合物的应用
AU2002357729A1 (en) 2001-11-16 2003-06-10 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
AU2002343094A1 (en) * 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
WO2003093498A1 (en) 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP1654247B1 (en) 2003-07-21 2010-01-20 Merck Serono SA Alkynyl aryl carboxamides
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
WO2005040102A2 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
CA2553775A1 (en) 2004-01-20 2005-08-11 Richard F. Harty Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
AR050631A1 (es) 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
WO2007050271A2 (en) 2005-10-25 2007-05-03 Wyeth 5-lipoxygenase modulators
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
IE20070928A1 (en) * 2007-12-21 2009-09-30 Giuliani Int Ltd Multi target ligands
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
US20090264520A1 (en) 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
FR2938338B1 (fr) 2008-11-13 2012-10-05 Galderma Res & Dev Modulateurs de l'acetyl-coenzyme a acyltransferase 1 ou 2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2396081T (pt) 2009-02-16 2017-07-11 Nogra Pharma Ltd Compostos alquilamido e suas utilizações
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2012102799A2 (en) 2011-01-28 2012-08-02 Shaver William A Method, composition and package for bowel cleansing
CA2841358A1 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
PL2775839T3 (pl) 2011-10-17 2024-04-08 The Regents Of The University Of California Sposoby oceny jakości odstraszania materiałów organicznych oraz sposoby i kompozycje do odstraszania stawonogów
WO2013064153A1 (en) 2011-10-31 2013-05-10 Claus Selch Larsen Prodrugs of non- steroid anti - inflammatory agents (nsaids)
US9044304B2 (en) 2011-12-23 2015-06-02 Alcon Lensx, Inc. Patient interface with variable applanation
CA2864059C (en) 2012-02-09 2020-04-28 Nogra Pharma Limited Methods of treating fibrosis
BR112014026160A2 (pt) 2012-04-18 2017-07-18 Nogra Pharma Ltd métodos para tratar intolerância à lactose
JP6096179B2 (ja) 2012-05-10 2017-03-15 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
AU2013269550A1 (en) 2012-06-01 2014-12-18 Nogra Pharma Limited Bicyclic heterocycles capable of modulating T-Cell responses, and methods of using same
CA2875964C (en) 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
BR112015005467A2 (pt) 2012-09-13 2017-07-04 Nogra Pharma Ltd métodos de tratar condições relacionadas ao cabelo
WO2014041141A1 (en) 2012-09-13 2014-03-20 Nogra Pharma Limited Methods of inhibiting hair growth
WO2014150377A1 (en) 2013-03-15 2014-09-25 Embry-Riddle Aeronautical University, Inc. Electrically coupled counter-rotation for gas turbine compressors
LT2978416T (lt) 2013-03-26 2016-12-12 Lipid Therapeutics Gmbh Farmacinė kompozicija, apimanti fosfatidilcholiną, skirtą opinio kolito gydymui
KR101423005B1 (ko) 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
ES2879826T3 (es) 2015-06-15 2021-11-23 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
CA3014575A1 (en) 2016-02-26 2017-08-31 Nogra Pharma Limited Methods of treating lactose intolerance
US20220000818A1 (en) 2019-01-25 2022-01-06 Nogra Pharma Limited Compositions for use in preventing acne
EA202192207A1 (ru) 2019-02-08 2021-10-27 Ногра Фарма Лимитед Способ получения 3-(4'-аминофенил)-2-метоксипропионовой кислоты и ее аналогов и промежуточных соединений
US11903592B2 (en) 2021-05-10 2024-02-20 DePuy Synthes Products, Inc. Data modules for surgical instruments

Also Published As

Publication number Publication date
WO2013117744A9 (en) 2013-10-03
EP3628317A1 (en) 2020-04-01
CN104254327A (zh) 2014-12-31
IL233968A (en) 2017-07-31
KR20140120936A (ko) 2014-10-14
IL253421B (en) 2018-07-31
MX2014009640A (es) 2014-11-12
EP2811993B1 (en) 2019-10-09
US20220033346A1 (en) 2022-02-03
IL233968A0 (en) 2014-09-30
JP2017222722A (ja) 2017-12-21
WO2013117744A2 (en) 2013-08-15
CA2864059C (en) 2020-04-28
US11753365B2 (en) 2023-09-12
US20150087708A1 (en) 2015-03-26
MX364220B (es) 2019-04-16
BR112014019399A2 (pt) 2017-07-04
JP2015508068A (ja) 2015-03-16
CN109999017A (zh) 2019-07-12
JP6523399B2 (ja) 2019-05-29
EP2811993A2 (en) 2014-12-17
WO2013117744A3 (en) 2013-11-21
IL260115A (en) 2018-07-31
IL253421A0 (en) 2017-09-28
JP6301844B2 (ja) 2018-03-28
KR102067848B1 (ko) 2020-01-17
CN116602950A (zh) 2023-08-18
US9682923B2 (en) 2017-06-20
AU2013217933A1 (en) 2014-08-21
US20180065921A1 (en) 2018-03-08
CA2864059A1 (en) 2013-08-15
AU2013217933B2 (en) 2017-11-30
US11046641B2 (en) 2021-06-29
EA030762B1 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
EA201491500A1 (ru) Способы лечения фиброза
EA201290919A1 (ru) Индазольные соединения и их применение
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201590987A1 (ru) Соединения и способы их применения
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201201374A1 (ru) Лечение атаксии-телеангиэктазии
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
EA201491854A1 (ru) Асимметрический синтез соединений спирооксиндола, полезных в качестве терапевтических средств
EA201370071A1 (ru) Способы и композиции для лечения рака легких
EA201591925A1 (ru) Терапевтические композиции и их применение